CHB Performance — Global X China Biotech Innovation ETF
Data updated: 2024-02-13
CHB returned −11.66% over one year to Nov 2023. The annualised 3-year return is −16.81%. The fund trailed its Emerging Markets Thematic Equity category average: $100 invested three years ago grew to $58, against $85 for the category, and to $88 over one year, against $99. Volatility over the past three years was 28.42% a year. In the 12 months to Nov 2023 the fund lost a net $16K, and assets reached $2.30M.
CHB Growth of $100
What $100 invested in Global X China Biotech Innovation ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Emerging Markets Thematic Equity category average over the same months.
| Period | CHB | Category average |
|---|---|---|
| 1 year (Dec 2022 – Nov 2023) | $88 | $99 |
| 3 years (Dec 2020 – Nov 2023) | $58 | $85 |
| Since data start (Sep 2020 – Nov 2023) | $56 | $85 |
CHB Trailing Returns
Total returns to Nov 2023, from SEC N-PORT.
| Period | Total return |
|---|---|
| 1 year | −11.66% |
| 3 years (annualised) | −16.81% |
CHB Annual Returns
Calendar-year total returns of Global X China Biotech Innovation ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2023 (Jan–Nov) | −5.04% |
| 2022 | −44.26% |
| 2021 | +11.62% |
| 2020 (Sep–Dec) | −5.46% |
CHB Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +9.4% | −1.0% | −10.0% | −0.2% | −6.4% | −8.8% | +4.0% | −6.1% | +5.3% | +6.6% | +4.3% | — |
| 2022 | −16.8% | −10.0% | −1.8% | −14.5% | −3.7% | −4.3% | −6.4% | +14.3% | +16.9% | −2.8% | −15.0% | −7.0% |
| 2021 | +6.2% | +9.7% | +1.2% | +16.1% | −4.6% | −6.0% | −6.2% | −1.4% | +2.0% | −3.5% | −1.7% | +1.4% |
| 2020 | — | — | — | — | — | — | — | — | −4.4% | +1.4% | — | −2.5% |
CHB Risk
Risk measures from monthly returns over Dec 2020 – Nov 2023.
- 3-year volatility (annualised): 28.42%
- 3-year Sharpe ratio: -0.75 (vs 4.5% risk-free rate)
- Best month: +16.91% (Sep 2022)
- Worst month: −16.84% (Jan 2022)
CHB Fund Flows
Monthly money in and out of Global X China Biotech Innovation ETF, from SEC Form N-PORT.
- 12-month net flow: −$16K
- 12-month gross sales (incl. reinvestments): −$16K
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Nov 2023 | $0 | $0 | $0 |
| Oct 2023 | $0 | $0 | $0 |
| Sep 2023 | $0 | $0 | $0 |
| Aug 2023 | $0 | $0 | $0 |
| Jul 2023 | $0 | $0 | $0 |
| Jun 2023 | $0 | $0 | $0 |
| May 2023 | $0 | $0 | $0 |
| Apr 2023 | $0 | $0 | $0 |
| Mar 2023 | −$16K | $0 | −$16K |
| Feb 2023 | $0 | $0 | $0 |
| Jan 2023 | $0 | $0 | $0 |
| Dec 2022 | $0 | $0 | $0 |
CHB Assets Under Management
Net assets of Global X China Biotech Innovation ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2023-11-30 | $2.30M |
| 2023-08-31 | $1.96M |
| 2023-05-31 | $2.22M |
| 2023-02-28 | $2.63M |
| 2022-11-30 | $2.61M |
| 2022-08-31 | $2.71M |
| 2022-05-31 | $2.65M |
| 2022-02-28 | $3.27M |
| 2021-11-30 | $4.31M |
| 2021-08-31 | $5.77M |
| 2021-05-31 | $6.63M |
| 2021-02-28 | $5.07M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.